Clinical characteristics of hydroxychloroquine retinopathy

British Journal of Ophthalmology

Volumn 95, Issue 2, 2011, Pages 245-250

  Payne, John F ^a   Hubbard III, G Baker ^a   Aaberg Sr , Thomas M ^a   Yan, Jiong ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLOR VISION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPERPIGMENTATION; LEAN BODY WEIGHT; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RETINA MACULA LUTEA; RETINOPATHY; TREATMENT OUTCOME; VISION; VISUAL ACUITY; VISUAL FIELD DEFECT;

AGED; ANTIRHEUMATIC AGENTS; COLOR VISION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; HYDROXYCHLOROQUINE; MIDDLE AGED; RETINAL DISEASES; RETROSPECTIVE STUDIES; VISUAL ACUITY;

EID: 79251481146     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.172148     Document Type: Article

References (21)

1. Rynes RI. Antimalarial drugs in the treatment of rheumatological diseases. Br J Rheumatol 1997;36:799-805. (Pubitemid 27348206)
2. Tehrani R, Ostrowski RA, Hariman R, et al. Ocular toxicity of hydroxychloroquine. Semin Ophthalmol 2008;23:201-9.
3. Yam JCS, Kwok AKH. Ocular toxicity of hydroxychloroquine. Hong Kong Med J 2006;12:294-304.
4. Levy GD, Munz SJ, Paschal J, et al. Incidence of hydroxychloroquine retinopathy in 1207 patients in a large multicenter outpatient practice. Arthritis Rheum 1997;40:1482-6.
5. Pai MP, Paloucek FP. The origin of the 'Ideal' body weight equations. Ann Pharmacol 2000;34:1066-9.
6. Bernstein HN. Ophthalmic considerations and testing in patients receiving long-term antimalarial therapy. Am J Med 1983;75:25-34.
7. Bernstein HN. Ocular safety of hydroxychloroquine. Ann Ophthalmol 1991;23:292-6.
8. Johnson MW, Vine AK. Hydroxychloroquine therapy in massive total doses without retinal toxicity. Am J Ophthalmol 1987;104:139-44.
9. Browning DJ. Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity. Am J Ophthalmol 2002;133:649-56.
10. Marmor MF, Carr RE, Easterbrook M, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the american academy of ophthalmology. Ophthalmology 2002;109:1377-82.
11. Easterbrook M. Defining ideal body weight. Am J Ophthalmol 2002;134:935; author reply 935-6.
12. Sanofi-Aventis. Plaquenil: prescribing information including black box warning. Bridgewater, NJ, USA: Sanofi-Aventis, 2006.
13. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996;39:723-31.
14. Lyons JS, Severns ML. Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography. Am J Ophthalmol 2007;143:801-9.
15. Chang WH, Katz BJ, Warner JEA, et al. A novel method for screening the mulifocal electroretinogram in patients using hydroxychloroquine. Retina 2008;28:1478-86.
16. Maturi RK, Minzhong Yu, Weleber RG. Multifocal electroretinographic evaluation of long-term hydroxychloroquine users. Arch Ophthalmol 2004;122:973-81.
17. So SC, Hedges TR, Schuman JS, et al. Evaluation of hydroxychloroquine retinopathy with multifocal electroretinography. Ophthalmic Surg Lasers Imaging 2003;34:251-8.
18. Lai TYY, Chan WM, Li H, et al. Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy. Am J Ophthalmol 2005;140:794-807.
19. Tzekov RT, Gerth C, Werner JS. Senescence of human multifocal electroretinogram components: a localized approach. Graefes Arch Clin Exp Ophthalmol 2004;242:549-60. (Pubitemid 39157682)
20. Marmor MF. The dilemma of hydroxychloroquine screening: new information from the multifocal ERG. Am J Ophthalmol 2005;140:894-5.
21. Block JA. Hydroxychloroquine and retinal safey. Lancet 1998;351:771.